Cost-Effectiveness Analysis of Antihypertensive Drugs in Hypertensive Patients with Diabetes Mellitus Comorbidity in Inpatient Patients of Bengkulu Province, Indonesia
Article Sidebar
Main Article Content
Abstract
In 2023, hypertensive inpatients with diabetes mellitus (DM) comorbidity were predominantly treated at Kaur Regional Hospital (KRH) and Harapan dan Doa Hospital (HDH) in Bengkulu Province, Indonesia. This study aimed to analyze the cost-effectiveness of inpatients of hypertension-DM therapy management strategies for social security administrators at KRH and HDH during 2022-2023. A cost-effectiveness analysis was conducted using retrospective medical records from January 2022 to December 2023. The drugs compared were amlodipine-captopril and bisoprolol-amlodipine. Additionally, KRH used candesartan-furosemide and HDH used amlodipine-candesartan as alternative treatments. The outcome parameter measured was a decrease in blood pressure. The analysis adopted the hospital perspective, focusing on direct cost components. The study included 112 and 118 patients from KRH and HDH, respectively, aged between 25 and 59. The incremental cost-effectiveness ratio (ICER) at KRH in 2022 was IDR 5,159/mmHg for systolic blood pressure reduction and IDR 4,711/mmHg for diastolic blood pressure reduction (comparing candesartan-furosemide with amlodipine-captopril). In 2023, the ICER was IDR 862,922/mmHg for systolic reduction and IDR 251,685/mmHg for diastolic reduction (comparing amlodipine-captopril with bisoprolol-amlodipine). At HDH in 2022, the ICER for systolic reduction was IDR 96,643/mmHg, and for diastolic reduction, it was IDR 2,967/mmHg (comparing amlodipine-captopril with bisoprolol-amlodipine). In 2023, the ICER was IDR 339,000/mmHg for systolic reduction (comparing amlodipine-candesartan with amlodipine-captopril) and IDR 37,474/mmHg for diastolic reduction (comparing amlodipine-captopril with bisoprolol-amlodipine). In conclusion, amlodipine-captopril was more cost-effective than bisoprolol-amlodipine at KRH in 2022 and HDH in 2023. However, switching to amlodipine-captopril required additional costs at KRH in 2023 and HDH in 2022.
Keywords:
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
1. Central Bureau of Statistics. Prevalence of High Blood Pressure by Province, 2016-2018. [Online]. 2021 [cited 2024 Oct 8]. Available from: https://www.bps.go.id/id/statistics-table/2/MTQ4MCMy/prevalensi-tekanan-darah-tinggi-menurut-provinsi.html
2. World Health Organization. Hypertension Indonesia 2023 Country Profile. 2023 [cited 2024 Oct 8]. Available from: https://www.who.int/publications/m/item/hypertension-idn-2023-country-profile
3. Fang H, Liu Q, Xi M, Xiong D, He J, Luo P, Li Z. Impact of comorbidities on clinical prognosis in 1280 patients with different types of COVID-19. J. Investig. Med. 2021; 69(1): 75-85. doi: 10.1136/jim-2020-001555
4. Armstrong C. JNC 8 guidelines for the management of hypertension in adults. Am. Fam. Physician. 2014; 90(7): 503-504. http://www.aafp.org/afp/2014/1001/p503.html
5. BPJS Kesehatan. Duties and Functions of BPJS Health. 2024 [cited 2024 Oct 8]. Available from: https://bpjs-kesehatan.go.id
6. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes (3rd ed). England: Oxford University Press; 2015. 369 p. doi: 10.1093/oso/9780198529446.001.0001
7. Ministry of Health of the Republic of Indonesia. Guidelines for the implementation of pharmacoeconomic studies. Jakarta, Indonesia: Directorate General of Pharmaceutical and Medical Devices; 2013. 96 p. Available from: https://farmalkes.kemkes.go.id/2014/02/pedoman-penerapan-kajian-farmakoekonomi/
8. Hollfelder J. Pharmacoeconomics in Public Health: Assessing Long-term Benefits. Pharmacoeconomics, 2024; 9: 247-248. doi: 10.37421/2472-1042.2024.9.247
9. Meltzer DO, Basu A, Sculpher MJ. Theoretical Foundations of Cost-Effectiveness Analysis in Health and Medicine. In: Neumann PJ, Ganiats TG, Russell LB, Sanders GD. Siegel JE (Eds), Cost-Effectiveness in Health and Medicine. 2nd ed. Oxford University Press, NY, USA, 2016. p. 39-66. doi: 10.1093/acprof:oso/9780190492939.003.0002
10. Tanjung R, Wardati Y, Saptarini NM. Cost-effectiveness analysis of prolanis of type 2 diabetes mellitus patients on three community health centers in Bandung, Indonesia. Int. J. Appl. Pharm. 2021; 13(special issue): 28-31. doi: 10.22159/IJAP.2021.V13S3.05
11. Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied Methods of Cost-Effectiveness Analysis in Healthcare. England: Oxford University Press; 2011. 156 p.
12. IBM SPSS Statistics 25 [cited 2024 April 9]. Available from: https://www.ibm.com/support/pages/downloading-ibm-spss-statistics-25
13. Scheffler WC. Statistics for Biology, Pharmacy, Medicine and Related Sciences. Bandung, Indonesia: ITB Bandung Publisher; 1987. 200 p.
14. Setiawan D, Endarti D, Suwantika AA. Pharmacoeconomic Modeling. Purwokerto, Indonesia: UMP Press; 2017. 324 p.
15. Ministry of Health of the Republic of Indonesia. Risk factors for hypertension. [Online]. 2019 [cited 2024 Oct 8]. Available from: https://p2ptm.kemkes.go.id/infographic-p2ptm/hipertensi-penyakit-jantung-dan-pembuluh-darah/faktor-risiko-penyebab-hipertensi
16. Degefu N, Edessa D, Getachew M, Motuma A, Regassa LD. In-hospital mortality and length of stay of patients with hypertensive crisis treated at public hospitals in Harari Regional State, Eastern Ethiopia. J. Clin. Hypertens. 2023; 25(10): 905–914. doi: 10.1111/jch.14728
17. Indonesian Society of Hypertension. Consensus on Management of Hypertension. [Online]. 2019 [cited 2024 Oct 8]. Available from: http://faber.inash.or.id/upload/pdf/article_Update_konsensus_201939.pdf
18. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003; 348(5): 383-393. doi: 10.1056/NEJMoa021778
19. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008; 359(15): 1577-1589. doi: 10.1056/NEJMoa0806470
20. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care 2018: 41(5): 917-928. doi: 10.2337/dci18-0007
21. Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care 2002; 25(7): 1159-1171. doi: 10.2337/diacare.25.7.1159
22. Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairn JA, Teerawattanon Y, Asfaw E, Lopert R, Culyer AJ, Walker DG. The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. Value Health 2016; 19(8):921-928. doi: 10.1016/j.jval.2016.04.015
23. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadhar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011; 378(9785): 31-40. doi: 10.1016/S0140-6736(11)60679-X
24. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination Therapy in Hypertension. J. Clin. Hypertens. 2011; 13(3),146–154. doi: 10.1111/j.1751-7176.2010.00397.x
25. Cohen BJ. A Fixed-Dose Combination of Bisoprolol and Amlodipine for Hypertension: A Potential Benefit to Selected Patients. Clin. Pharmacol. Drug Dev. 2017; 6(1): 6-8. doi: 10.1002/cpdd.325
26. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Int. J. Epidemiol. 2007; 36(2): 476-477. doi: 10.1093/ije/dym062
27. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 2008; 358(6): 580-591. doi: 10.1056/NEJMoa0706245
28. Siegel KR, Ali MK, Zhou X, Ng BP, Jawanda S, Proia K, Zhang X, Gregg EW, Albright AL, Zhang P. Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008? Diabetes Care 2020; 43(7): 1557-1592. doi: 10.2337/dci20-0017
29. Knowler WC, Barrett-Connor E, Fowlwe SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346(6): 393-403. doi: 10.1056/nejmoa012512
30. Verhoeven F, Tanja-Dijkstra K, Nijland N, Evsenbach G, van Gemert-Pijnen L. Asynchronous and synchronous teleconsultation for diabetes care: a systematic literature review. J. Diabetes. Sci. Technol. 2010; 4(3): 666-84. doi: 10.1177/193229681000400323